Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Immunology|August 31, 2002
A mouse strain defective for alphabeta versus gammadelta T cell lineage commitmentElisabeth Mertsching, Andrea L Wurster, Carol Katayama, et al.
Clinical Immunology (Orlando, Fla.)|June 28, 2008
Systemic administration of an Fcgamma-Fc(epsilon)-fusion protein in house dust mite sensitive nonhuman primatesMichael R Van Scott, Elisabeth Mertsching, Ella Negrou, et al.
The Journal of Biological Chemistry|August 15, 2006
An intermediate pH unfolding transition abrogates the ability of IgE to interact with its high affinity receptor FcepsilonRIalphaStephen J Demarest, Jennifer Hopp, Julie Chung, et al.
The Journal of Allergy and Clinical Immunology|October 24, 2007
A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatasesElisabeth Mertsching, Lisa Bafetti, Henry Hess, et al.
Protein Science : a Publication of the Protein Society|January 7, 2010
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinasesDouglas J Marcotte, Yu-Ting Liu, Robert M Arduini, et al.
Cellular & Molecular Immunology|December 5, 2019
Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responsesRyan A Adams, Cátia Fernandes-Cerqueira, Antonella Notarnicola, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2022
Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse modelGeorge H Vandeveer, Robert M Arduini, Darren P Baker, et al.
Bioorganic & Medicinal Chemistry|May 30, 2019
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screensBrian T Hopkins, Eris Bame, Noah Bell, et al.
Bioorganic & Medicinal Chemistry|July 27, 2021
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitorsBrian T Hopkins, Eris Bame, Noah Bell, et al.
Pageof 1